Daily intraperitoneal Ganciclovir strongly inhibited EAE and neuroinflammation in mice compared with PBS vehicle. In aged naïve mice, Ganciclovir treatment produced a trending reduction in the population expressing SA‐β‐gal within lung CD45+ cells. In another study of aged mice, Ganciclovir decreased blood–brain barrier permeability for all fluorescent tracers tested compared with vehicle, bringing permeability closer to young control levels. [1,2,3]
GCV strongly inhibits EAE and neuroinflammation beginning at 7 d.p.i.
Animal study · mice; EAE; n = 10–15 mice/group [1]
Mice were treated daily with PBS (vehicle) or 100 mg/kg GCV beginning at 7 d.p.i. GCV strongly inhibits EAE and neuroinflammation.
Conditions shared by the study groups
- Route
- intraperitoneal injections
- Treatment course
- daily; beginning at 7 d.p.i.
- Vehicle
- PBS
- Ganciclovir 100 mg/kg
- Model: mice; EAE; n = 10–15 mice/group
Methods and source locations
Compound reported in the paper: Ganciclovir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIAL AND METHODS > Untitled > GCV, IFN-β, and mitoxantrone treatments. (S11); Figure 1. legend (S70); Figure 2. legend (S100, S101, S103, S104)
Disease severity: Disease severity; comparator: PBS (vehicle) — Figure 2. legend (S100, S101, S103)
Ganciclovir 100 mg/kg · MATERIAL AND METHODS > Untitled > GCV, IFN-β, and mitoxantrone treatments. (S11); Figure 2. legend (S100, S101)
Lung senescence marker expression in aged mice
Animal study · aged (18–20mo) male and female p16‐3MR mice on a C57BL/6 genetic background; Between 4 and 8 aged mice per treatment group [2]
Aged male and female mice received intraperitoneal Ganciclovir or equal-volume PBS injections. In naïve mouse lungs, the Ganciclovir-treated group showed a trending reduction in the population expressing SA‐β‐gal within CD45+ cells.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- five consecutive days
- Vehicle
- PBS
- Ganciclovir 25 mg/kg/day
- Model: aged (18–20mo) male and female p16‐3MR mice on a C57BL/6 genetic background; Between 4 and 8 aged mice per treatment group
Methods and source locations
Compound reported in the paper: Ganciclovir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
METHODS > Mice (S1, S2); METHODS > Ganciclovir (GCV) treatment (S8, S9, S10); RESULTS > Untitled (S58, S60)
In the CD45+ population; population expressing SA‐β‐gal (Q1): In the CD45+ population; population expressing SA‐β‐gal (Q1); comparator: Control mice were injected with equal volume PBS. — METHODS > Ganciclovir (GCV) treatment (S8); RESULTS > Untitled (S58, S60)
Ganciclovir 25 mg/kg/day · METHODS > Ganciclovir (GCV) treatment (S8, S10); RESULTS > Untitled (S58, S60)
Ganciclovir Decreases Blood–Brain Barrier Permeability in Aged Mice
Animal study · aged p16‐3MR mice [3]
Aged mice received intraperitoneal Ganciclovir, with vehicle as the control. Senolytic treatment with Ganciclovir effectively decreased blood–brain barrier permeability for all fluorescent tracers tested, bringing permeability closer to levels observed in young control mice.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- daily; 5 days, across two treatment cycles, with a 2‐week resting period between cycles
- Vehicle
- PBS
- Ganciclovir 25 mg/kg
- Model: aged p16‐3MR mice
Methods and source locations
Compound reported in the paper: Ganciclovir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Senolytic Treatments (S13, S14); Materials and Methods > Cranial Window Surgery Protocol (S141); Materials and Methods > Measurement of Blood–Brain Barrier Integrity and Microvascular Density Using Intravital Two‐Photon Microscopy (S145, S148); FIGURE 5 legend (S372, S377)
Two‐photon‐imaging‐based measurement of microvascular permeability to fluorescent tracers: Two‐photon‐imaging‐based measurement of microvascular permeability to fluorescent tracers; comparator: vehicle — FIGURE 5 legend (S372, S377)
Ganciclovir 25 mg/kg · Materials and Methods > Senolytic Treatments (S13, S14); FIGURE 5 legend (S377)